Is Sanofi (ENXTPA:SAN) Still Undervalued After Its Eczema Drug Setback?

Sanofi stock has been slightly positive over the past five years, yet its recent share price weakness and strong valuation checks suggest the market may be pricing the company more cautiously than the fundamentals imply.

• Sanofi has returned about 8.4% over the past five years, which points to a modest overall gain rather than a strong long term rerating.
• The expanded research collaboration with Aqemia can support long term growth expectations, while the decision to discontinue amlitelimab for eczema after a Phase III setback highlights the ongoing clinical and pipeline risks that can affect how investors value Sanofi.
• Sanofi screens as cheap on the broader tests, with the stock coming out undervalued on 6 of 6 valuation checks.

The issue now is whether Sanofi's current share price properly reflects this mix of steady long term returns, pipeline uncertainty, and a valuation profile that suggests the stock may be trading below what the fundamentals imply.

Find out why Sanofi's -5.7% return over the last year is lagging behind its peers.

Does Sanofi Look Undervalued on Earnings?

The P/E ratio is a useful way to look at Sanofi because earnings are a key driver of how investors typically value large pharmaceutical stocks. Sanofi trades on a P/E of about 18.9x, slightly below both the peer average of 19.2x and the wider pharmaceuticals industry average of 20.8x. This places it at a modest discount to comparable companies on earnings.

The fair P/E ratio, which reflects what investors might usually pay for a company with Sanofi’s profile, is about 35.7x. That is a wide gap to the current 18.9x. This indicates the stock is pricing in a cautious view on earnings despite the extended collaboration with Aqemia and ongoing pipeline work after the amlitelimab setback. If the market were to value Sanofi closer to that fair ratio, the implied earnings multiple would be materially higher than today’s level.

On an earnings multiple basis, Sanofi stock currently appears undervalued compared with the tailored fair P/E benchmark.

See what the numbers say about this price — find out in our valuation breakdown.

The Sanofi Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Sanofi's valuation puzzle leaves off. They spell out which growth, margin and earnings paths would need to play out for the stock to be worth materially more or less than today's price on the Community page. Each Sanofi narrative is framed as a thesis about the business that can be revisited over time, so you can see how the underlying assumptions hold up as new information emerges.

One of the top community narratives on Sanofi: 21% undervalued

"Sanofi's ongoing focus on innovative product launches and its strong R&D pipeline, highlighted by accelerating investments, multiple Phase III readouts through 2026, and continued expansion of biologics, position the company to capture higher demand for chronic disease treatments in a world with an aging population..."

Read one of the top narratives on Sanofi

Do you think there's more to the story for Sanofi? Head over to our Community to see what others are saying!

The Bottom Line

Sanofi appears undervalued on earnings multiples, with the current P/E sitting well below the tailored fair ratio that similar companies often attract. The key question is whether that discount reflects genuine concern around the pipeline setbacks highlighted earlier, or whether the market is simply being overly cautious about the earnings outlook. For readers, the crux is whether Sanofi can continue converting its R&D efforts and collaborations into profits that justify a higher multiple, or whether the present gap between price and fundamentals turns out to be a value trap rather than an opportunity.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com